The Medicines Company
MDCO today announced that it has voluntarily discontinued
its Phase 2b dose-ranging study of MDCO-2010, a serine protease
inhibitor which was being developed to reduce blood loss during
surgery. This action was taken in response to serious unexpected
patient safety issues encountered during the trial, which had so far
recruited 44 of a planned 90 patients in the first stage of the
study.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in